Association of mutant EGFR concentration in circulating cell-free DNA (cfDNA) by ddPCR with tumor burden and prognosis in NSCLC patients treated with EGFR-TKIs.

被引：1
|
作者：
Zhu, Yan-juan
Zhang, Hai-bo
Liu, Yi-hong
Zhang, Fu-li
Zhu, Ya-zhen
Zheng, Guang-juan
Chen, Jun
Li, Yong
Bai, Jian-ping
Liu, Li-rong
Qu, Yan-chun
Qu, Xin
Chen, Xian
Li, Yan
机构：
[1] Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China
[2] WuXi AppTec, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e23063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23063
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
    Zhu, Yan-juan
    Zhang, Hai-bo
    Liu, Yi-hong
    Zhang, Fu-li
    Zhu, Ya-zhen
    Li, Yong
    Bai, Jian-ping
    Liu, Li-rong
    Qu, Yan-chun
    Qu, Xin
    Chen, Xian
    Li, Yan
    Zheng, Guang-juan
    ONCOTARGET, 2017, 8 (08) : 13195 - 13205
  • [2] Dynamic monitoring and predictive value of circulating tumor cells in EGFR mutant advanced NSCLC patients treated with first-line EGFR-TKIs.
    Su, ChunXia
    Jiang, Tao
    Zhao, Jing
    Zhao, Chao
    Li, Xuefei
    Shen, Jiqiao
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients
    Zhu, Yan-juan
    Zhang, Hai-bo
    Liu, Yi-hong
    Zhang, Fu-li
    Zhu, Ya-zhen
    Li, Yong
    Bai, Jian-ping
    Liu, Li-rong
    Qu, Yan-chun
    Qu, Xin
    Chen, Xian
    Li, Yan
    Zheng, Guang-juan
    LUNG CANCER, 2017, 109 : 124 - 127
  • [4] Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC
    Zhu, Yan-Juan
    Zhang, Hai-Bo
    Liu, Yi-Hong
    Zhu, Ya-Zhen
    Chen, Jun
    Li, Yong
    Bai, Jian-Ping
    Liu, Li-Rong
    Qu, Yan-Chun
    Qu, Xin
    Chen, Xian
    Zheng, Guang-Juan
    ONCOLOGY LETTERS, 2017, 14 (02) : 2573 - 2579
  • [5] Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs.
    Lin, Jessica Jiyeong
    Cardarella, Stephanie
    Lydon, Christine A.
    Dahlberg, Suzanne Eleanor
    Jackman, David Michael
    Janne, Pasi A.
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with erlotinib.
    Yanagita, Masahiko
    Paweletz, Cloud
    O'Connell, Allison
    Jackman, David Michael
    Kuang, Yanan
    Oxnard, Geoffrey R.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Applications of cell-free circulating tumor DNA detection in EGFR mutant lung cancer
    Bulbul, Ajaz
    Leal, Alessandro
    Husain, Hatim
    JOURNAL OF THORACIC DISEASE, 2020, 12 (05) : 2877 - 2882
  • [8] Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs
    S. Chen
    J. Zhao
    L. Cui
    Y. Liu
    Clinical and Translational Oncology, 2017, 19 : 332 - 340
  • [9] Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs
    Chen, S.
    Zhao, J.
    Cui, L.
    Liu, Y.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (03): : 332 - 340
  • [10] Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs
    Su, C.
    Jiang, T.
    Zhao, J.
    Li, X.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S409 - S410
12345